Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
1. Median progression-free survival was 11.4 months in the amivantamab–chemotherapy group and 6.7 months in the chemotherapy group with HR ...
Tag: exon 20
1. Median progression-free survival was 11.4 months in the amivantamab–chemotherapy group and 6.7 months in the chemotherapy group with HR ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
